OXYCODONE HYDROCHLORIDE


Trade Names	OXAYDO OXYCODONE HYDROCHLORIDE OXYCONTIN ROXICODONE ROXYBOND
Synonyms	Abtard Candox Carexil Dolocodon pr Endocodone Leveraxo Longtec Lynlor Oxaydo Oxecta Oxeltra Oxycodone hcl Oxycodone hydrochloride Oxycodone hydrochloride cii Oxycontin Oxylan Oxynorm Reltebon Roxicodone Roxybond Shortec Zomestine
Status
Molecule Category	Salt
UNII	C1ENJ2TE6C
Parent Compound:


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MUZQPDBAOYKNLO-RKXJKUSZSA-N
Smiles	COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl
InChI	InChI=1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H22ClNO4
Molecular Weight	351.83
AlogP	1.05
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	59.0
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	23.0

Pharmacology

Mechanism of Action	Action	Reference
Mu opioid receptor agonist	AGONIST	DailyMed


Protein: Mu opioid receptor Description: Mu-type opioid receptor Organism : Homo sapiens P35372 ENSG00000112038

Cross References

Resources	Reference
ChEBI	7859
ChEMBL	CHEMBL1200890
FDA SRS	C1ENJ2TE6C
KEGG	C08026
PubChem	5462350
SureChEMBL	SCHEMBL30095

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).